GGrantIndex
← Leaderboards

Susan B Zolla-Pazner

New York University School Of Medicine

$26,881,465
Attributed
$26,881,465
Total exposure
12
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $3.8M · FY200517
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

NIH$42,280,012 · 13

By mechanism

P01$19,795,719 · 2
R01$14,043,247 · 2
P30$4,609,653 · 5
D43$2,541,323 · 1
R56$616,274 · 1
R21$506,250 · 1

Top collaborators

Most similar at New York University School Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Hiv Infections

Research focus

Hiv InfectionsVirusSerumEpitopesDesignAntibodiesCellsBaseHiv-1ProductionHiv Envelope Protein Gp120MediatingVirionVaccinesStructureVaccine DesignPreventionSpecificityHiv VaccineMonoclonal AntibodyCameroonNeutralizing AntibodyImmune ResponseViral

Grant awards (62)

Epitope-targeted Vaccines for HIV-1 Prevention$2,525,880
P01 · FY2017 · AI
Vaccines to Induce Functional Antibodies Targeting the V2 Loop$814,846
P01 · FY2017 · AI · contact PI
Epitope-targeted Vaccines for HIV-1 Prevention$3,002,577
P01 · FY2016 · AI
Vaccines to Induce Functional Antibodies Targeting the V2 Loop$784,933
P01 · FY2016 · AI · contact PI
Epitope-targeted Vaccines for HIV-1 Prevention$2,816,030
P01 · FY2015 · AI
Vaccines to Induce Functional Antibodies Targeting the V2 Loop$899,104
P01 · FY2015 · AI · contact PI
Epitope-targeted Vaccines for HIV-1 Prevention$2,135,189
P01 · FY2014 · AI
Protective Human Monoclonal Antibodies to HIV-1$799,591
R01 · FY2014 · HL · contact PI
Vaccines to Induce Functional Antibodies Targeting the V2 Loop$556,733
P01 · FY2014 · AI · contact PI
Recovery of HIV Monoclonal Antibody Inventory Lost after Hurricane Sandy$167,546
R24 · FY2014 · OD · contact PI
Epitope-targeted Vaccines for HIV-1 Prevention$2,532,157
P01 · FY2013 · AI
Vaccines to Induce Functional Antibodies Targeting the V2 Loop$718,447
P01 · FY2013 · AI · contact PI
Epitope-targeted Vaccines for HIV-1 Prevention$2,386,714
P01 · FY2012 · AI
Protective Human Monoclonal Antibodies to HIV-1$800,269
R01 · FY2012 · HL · contact PI
Vaccines to Induce Functional Antibodies Targeting the V2 Loop$623,109
P01 · FY2012 · AI · contact PI
Protective Human Monoclonal Antibodies to HIV-1$808,654
R01 · FY2011 · HL · contact PI
Epitope-Targeted Vaccine for HIV-1 Prevention$616,274
R56 · FY2011 · AI · contact PI
Protective Human Monoclonal Antibodies to HIV-1$800,505
R01 · FY2010 · HL · contact PI
Developmental Core$66,462
P30 · FY2010 · AI · contact PI
Protective Human Monoclonal Antibodies to HIV-1$785,373
R01 · FY2009 · HL · contact PI
DEVELOPMENTAL CORE$500,665
P30 · FY2009 · AI · contact PI
VIRAL IMMUNOLOGY CORE$389,223
P30 · FY2009 · AI · contact PI
Protective Human Monoclonal Antibodies to HIV-1$735,382
R01 · FY2008 · HL · contact PI
Design and Use of HIV V3 Mimetic Immunogens$643,919
R01 · FY2008 · AI · contact PI
DEVELOPMENTAL CORE$525,879
P30 · FY2008 · AI · contact PI
VIRAL IMMUNOLOGY CORE$408,823
P30 · FY2008 · AI · contact PI
Protective Human Monoclonal Antibodies to HIV1$652,417
R01 · FY2007 · HL · contact PI
Design and Use of HIV V3 Mimetic Immunogens$637,825
R01 · FY2007 · AI · contact PI
DEVELOPMENTAL CORE$326,360
P30 · FY2007 · AI · contact PI
VIRAL IMMUNOLOGY CORE$284,953
P30 · FY2007 · AI · contact PI
Design and Use of HIV V3 Mimetic Immunogens$638,312
R01 · FY2006 · AI · contact PI
Protective Human Monoclonal Antibodies to HIV1$634,239
R01 · FY2006 · HL · contact PI
Training Program in TB and HIV Prevention and Treatment$426,323
D43 · FY2006 · TW · contact PI
DEVELOPMENTAL CORE$323,297
P30 · FY2006 · AI · contact PI
VIRAL IMMUNOLOGY CORE$277,443
P30 · FY2006 · AI · contact PI
Design and Use of HIV V3 Mimetic Immunogens$635,217
R01 · FY2005 · AI
Protective Human Monoclonal Antibodies to HIV1$629,718
R01 · FY2005 · HL
DEVELOPMENTAL CORE$619,458
P30 · FY2005 · AI
VIRAL IMMUNOLOGY CORE$544,940
P30 · FY2005 · AI
TRAINING PROGRAM IN TB AND HIV PREVENTION AND TREATMENT$400,000
D43 · FY2005 · TW
Design and Use of HIV V3 Mimetic Immunogens$665,082
R01 · FY2004 · AI
Protective Human Monoclonal Antibodies to HIV1$611,476
R01 · FY2004 · HL
TRAINING PROGRAM IN TB AND HIV PREVENTION AND TREATMENT$400,000
D43 · FY2004 · TW
Protective Human Monoclonal Antibodies to HIV1$623,923
R01 · FY2003 · HL
TRAINING PROGRAM IN TB AND HIV PREVENTION AND TREATMENT$300,000
D43 · FY2003 · TW
Human Monoclonal Antitoxin to Anthrax Protective Antigen$253,500
R21 · FY2003 · AI
The Establishment of a New AITRP Site in Shanghai$100,000
D43 · FY2003 · TW
IMMUNOLOGIC RELATEDNESS AMONG AND BETWEEN HIV1 CLADES$692,196
R01 · FY2002 · AI
TRAINING PROGRAM IN TB AND HIV PREVENTION AND TREATMENT$315,000
D43 · FY2002 · TW
Human Monoclonal Antitoxin to Anthrax Protective Antigen$252,750
R21 · FY2002 · AI
CORE--DEVELOPMENTAL FACILITY$0
P30 · FY2002 · AI
CORE--IMMUNOLOGY FACILITY$0
P30 · FY2002 · AI
IMMUNOLOGIC RELATEDNESS AMONG AND BETWEEN HIV1 CLADES$673,979
R01 · FY2001 · AI
PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1$451,939
R01 · FY2001 · HL
TRAINING PROGRAM IN TB AND HIV PREVENTION AND TREATMENT$300,000
D43 · FY2001 · TW
CORE--DEVELOPMENTAL FACILITY$171,075
P30 · FY2001 · AI
CORE--IMMUNOLOGY FACILITY$171,075
P30 · FY2001 · AI
CORE--DEVELOPMENTAL FACILITY$0
P30 · FY2001 · AI
CORE--IMMUNOLOGY FACILITY$0
P30 · FY2001 · AI
IMMUNOLOGIC RELATEDNESS AMONG AND BETWEEN HIV1 CLADES$671,292
R01 · FY2000 · AI
PROTECTIVE HUMAN MONOCLONAL ANTIBODIES TO HIV1$451,939
R01 · FY2000 · HL
TRAINING PROGRAM IN TB AND HIV PREVENTION AND TREATMENT$300,000
D43 · FY2000 · TW